Migdal Insurance & Financial Holdings Ltd. Protalix Bio Therapeutics, Inc. Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.18 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 02, 2022	SELL	$0.81 - $1.17 $1,969 - $2,845	-2,432 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$0.81 - $1.33 $1,270 - $2,085	-1,568 Reduced 39.2%	2,432 $2,000
Q3 2021 Nov 16, 2021	BUY	$1.31 - $1.87 $5,240 - $7,480	4,000 New	4,000 $5,000

Others Institutions Holding PLX

# of Institutions

Shares Held

3.58M

Call Options Held

61.1K

Put Options Held

36.2K

Jim Simons Renaissance Technologies LLC | New York, Ny

956K
Shares

$1.67 Million
0.0% of portfolio
Gsa Capital Partners LLP London, X0

435K
Shares

$761,622
0.03% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

374K
Shares

$654,074
0.0% of portfolio
Black Rock Inc. New York, NY

333K
Shares

$583,049
0.0% of portfolio
Stratos Wealth Partners, Ltd.

270K
Shares

$472,500
0.0% of portfolio

View Full List

About Protalix BioTherapeutics, Inc.

Ticker PLX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,753,400
Market Cap $87.1M
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...

More about PLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account